Life Spine received FDA 510(k) clearance to market the PRO-LINK® Ti Standalone Cervical Spacer. Full launch is scheduled for the end of 4Q16.
PRO-LINK Ti features the Osseo-Loc™ proprietary surface treatment for titanium with 500 to 600 microns of porosity to support bone growth. The implant includes lateral graft windows to enhance bone graft volume and visibility.
Life Spine announced 2Q16 revenue growth at +50% vs. 2Q15, and 1H16 revenue +44% vs. the previous year. PRO-LINK Ti is one of 20 new products for launch from Life Spine during 2016.
Life Spine received FDA 510(k) clearance to market the PRO-LINK® Ti Standalone Cervical Spacer. Full launch is scheduled for the end of 4Q16.
PRO-LINK Ti features the Osseo-Loc™ proprietary surface treatment for titanium with 500 to 600 microns of porosity to support bone growth. The implant includes lateral graft windows to enhance bone graft...
Life Spine received FDA 510(k) clearance to market the PRO-LINK® Ti Standalone Cervical Spacer. Full launch is scheduled for the end of 4Q16.
PRO-LINK Ti features the Osseo-Loc™ proprietary surface treatment for titanium with 500 to 600 microns of porosity to support bone growth. The implant includes lateral graft windows to enhance bone graft volume and visibility.
Life Spine announced 2Q16 revenue growth at +50% vs. 2Q15, and 1H16 revenue +44% vs. the previous year. PRO-LINK Ti is one of 20 new products for launch from Life Spine during 2016.
Copy to clipboard 
